title: Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.
abstract: Despite attaining LDL-cholesterol targets, many patients with diabetes remain at risk of developing cardiovascular events. In addition, treatment with statins has been associated with a slight but significant increased risk of development of diabetes, particularly with high-intensity statins. Pitavastatin is a moderate- to high-intensity statin that effectively reduces LDL-cholesterol levels. Pitavastatin provides a sustained increase of HDL-cholesterol levels that may exhibit a neutral or positive effect on glucose metabolism, may not increase the risk of new-onset diabetes, may exhibit positive effects on renal function and urinary albumin excretion and the risk of drug-drug interactions is low. Therefore, it seems that pitavastatin should preferentially be considered in the treatment of dyslipidemia in diabetic patients or at risk of developing diabetes.
authors.affiliation: Cardiology Department, Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.affiliation: Cardiology Department, Hospital La Paz, Madrid, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Escobar
mesh_terms: D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D003920:Diabetes Mellitus / Q000097:blood*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; C108475:pitavastatin
keywords: HDL-cholesterol; diabetes; dyslipidemia; metabolic syndrome; pitavastatin